170 Tumor Genomics and Cancer Genetics Tumor Board (072017)

Dallas, TX US
July 20, 2017

Discuss the clinical implications of somatic/tumor genomic testing in oncology care. Discuss the management of patients found to have potentially "actionable" somatic mutation in a multidisplinary setting. Multidisciplinary review of somatic genomic testing results to discuss prognosis and potential alternative therapeutics, clinical trials etc. Recogonize the implications of incidental germline mutations that can be identified with tumor genomic testing and discuss further testing and mangement.

Target Audience

Medical Radiation, and Surgical Oncologists; Radiologists; Pathologists; Urologists; Neurologists; Genetic Counselors; UTSW Faculty, Fellows and Residents in training; and private practice oncologists.

Learning Objectives

At the conclusion of this activity, the participant should be able to: 1. Understand how genomic testing may alter treatment decisions and provide full follow up of tumor genomics testing. 2. Interpret a tumor genomic report. 3. Identify incidental germline findings in a genomic report. 4. Plan and implement clinical management of patients with a germline genetic mutation. 5. Explain how to properly consent a patient undergoing tumor genomic testing.

Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
07/20/2017
Course expires: 
07/20/2017
Event starts: 
07/20/2017 - 5:30pm CDT
Event ends: 
07/20/2017 - 6:30pm CDT
Cost:
$0.00
Part of: 
170 Molecular Tumor Board
Add to calendar: 
UT Southwestern Medical Center
5323 Harry Hines Blvd.
ND3.218
Dallas, TX 75390
United States

 

 

 

 

 

 

 

 

 

 

Kevin Cederberg, M.D

 

 

 

 

 

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.